| Breakthrough Trichosporon asahii infection in a patient with acute myeloid leukemia receiving micafungin |
|
Seo Young Sohn, Jung Won Noh, Ga Yeon Lee, Bok Soon Chang, Dong Hwan Kim, Jun Ho Jang, Chul Won Jung |
|
|
| Micafungin을 투여받은 백혈병 환자에서 발생한 Trichosporon 감염증 |
|
손서영·노정원·이가연·장복순·김동환·장준호·정철원, Jung Won Noh, Ga Yeon Lee, Bok Soon Chang, Dong Hwan Kim, Jun Ho Jang, Chul Won Jung |
|
|
|
|
|
|
| Abstract |
|
Micafungin is a recently approved echinocandin with broad spectrum activity against Candida and Aspergillus species.
However, this agent has limited activity against a number of fungi, including Trichosporon. We report a case of Trichosporon asahii
fungemia in a 65 year old woman with acute myeloid leukemia that developed after 10 days of empirical micafungin therapy.
Trichosporonosis was successfully treated with voriconazole and she achieved complete hematologic remission.
After consolidation therapy, T. ashaii fungemia redeveloped, despite empirical amphotericin therapy for neutropenic fever. This
was also controlled successfully with voriconazole.
Because the use of micafungin is expected to increase, due to its effective antifungal activity, the possibility of breakthrough trichosporonosis
should be considered in patients receiving micafungin. Voriconazole may be effective in controlling disseminated
T. ashaii infection in neutropenic patients. (Korean J Med 77:S1318-S1322, 2009) |
| Key Words:
Trichosporon; Micafungin; Voriconazole |
|
PDF Links
Full text via DOI
Download Citation
